journal article·2015-01Open access

Ultrathin Iron Oxide Nanowhiskers as Positive Contrast Agents for Magnetic Resonance Imaging

Thomas Macher, John Totenhagen, Jennifer Sherwood, Ying Qin, Demet Gurler, Mark S. Bolding, Yuping Bao

Advanced Functional Materials· Volume 25· Issue 3

Abstract

In this paper, a highly innovative concept of using ultrathin iron oxide nanowhiskers as a positive (T1) contrast agent for magnetic resonance imaging (MRI) is demonstrated. Iron oxide nanowhiskers with dimensions of approximately 2 nm × 20 nm are synthesized by heating an iron oleate/oleylamine complex under 150 °C. These nanostructures have very high surface‐to‐volume ratios, leading to strong paramagnetic signal, a property suitable for T1 contrast in MRI. The positive contrast enhancement of these nanowhiskers is demonstrated in vitro and in vivo in a rat model. Successful development of this technology has substantial commercial value in biomedical imaging, potentially leading to the advancement of human healthcare technologies.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Characterization and Applications of Magnetic Nanoparticles · Lanthanide and Transition Metal Complexes · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Chemical and Biological Engineering Alabama Innovation and Mentoring of Entrepreneurs The University of Alabama Tuscaloosa AL 35487 USA

Department of Radiology The University of Alabama at Birmingham Birmingham AL 35233 USA

Alabama Innovation and Mentoring of Entrepreneurs The University of Alabama Tuscaloosa AL 35487 USA

References (36)

Show source-provided references
1. 10.1021/cr100025t10.1021/cr100025t ↗
2. 10.1007/s00395-008-0711-610.1007/s00395-008-0711-6 ↗
3. 10.2174/18715200778061813510.2174/187152007780618135 ↗
4. FDA approval for Feridex iv liver contrast agent. Drug News Perspectives1996 9 422–422.
5. 10.1007/s00330-002-1721-710.1007/s00330-002-1721-7 ↗
6. 10.1517/1742525090287379610.1517/17425250902873796 ↗
7. 10.1148/radiol.1313166910.1148/radiol.13131669 ↗
8. http://www.fda.gov/Drugs/DrugSafety/ucm223966.htm(accessed: June 2011).
9. 10.1039/C1CS15248C10.1039/C1CS15248C ↗
10. 10.1002/jmri.188004050810.1002/jmri.1880040508 ↗
11. 10.2174/1381612811319999040910.2174/13816128113199990409 ↗
12. 10.1007/s11307-010-0402-110.1007/s11307-010-0402-1 ↗
13. 10.1016/S0169-409X(98)00103-310.1016/S0169-409X(98)00103-3 ↗
14. 10.2214/ajr.152.1.16710.2214/ajr.152.1.167 ↗
15. 10.1148/radiology.168.2.339364910.1148/radiology.168.2.3393649 ↗
16. 10.1002/ajh.2165610.1002/ajh.21656 ↗
17. Lin C. H. · J. Nanomater. · 2012 · 734842 · 1
18. 10.1002/mrm.2249810.1002/mrm.22498 ↗
19. 10.1016/j.mri.2011.04.01110.1016/j.mri.2011.04.011 ↗
20. 10.1021/cm200414c10.1021/cm200414c ↗
21. 10.1021/nl902715v10.1021/nl902715v ↗
22. 10.1002/ejic.20090017310.1002/ejic.200900173 ↗
23. 10.1021/la063415s10.1021/la063415s ↗
24. 10.1002/adfm.20110312310.1002/adfm.201103123 ↗
25. 10.2217/17435889.3.5.70310.2217/17435889.3.5.703 ↗
26. 10.1021/nl200136j10.1021/nl200136j ↗
27. 10.1063/1.335589910.1063/1.3355899 ↗
28. 10.1016/j.jmmm.2007.03.08510.1016/j.jmmm.2007.03.085 ↗
29. 10.1007/s10051005107910.1007/s100510051079 ↗
30. 10.1002/pssa.20056310410.1002/pssa.200563104 ↗
31. 10.1016/j.jmmm.2006.09.01110.1016/j.jmmm.2006.09.011 ↗
32. 10.1166/jnn.2008.B01210.1166/jnn.2008.B012 ↗
33. Nakamoto K. · 1986
34. 10.1016/0162-0134(94)80025-110.1016/0162-0134(94)80025-1 ↗
35. 10.1021/nn900373b10.1021/nn900373b ↗
36. 10.1021/nl071099b10.1021/nl071099b ↗